Navigation Links
OncoGenex Pharmaceuticals Added to Russell Indexes
Date:6/30/2009

true opportunity set.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $4 trillion in assets currently are benchmarked to them. These investment tools originated from Russell's multi-manager investment business in the early 1980s when the company saw the need for a more objective, market-driven set of benchmarks in order to evaluate outside investment managers.

Total returns data for the Russell 3000 and other Russell Indexes is available at http://www.russell.com/Indexes/performance/default.asp.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase 2 clinical trials in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to effectively target and inhibit production of specific proteins in tumor cells. OncoGenex and Isis partnered in the successful discovery of OGX-011, OGX-427 and OGX-225 and with respect to OGX-011, in its initial development. In 2008, OncoGenex and Isis amended their
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. OncoGenex Pharmaceuticals Files Shelf Registration Statement
2. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
3. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
4. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
5. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
6. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
7. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
8. OncoGenex Reports First Quarter Financial Results
9. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
10. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
11. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Fla. , May 21, 2013  On ... FCN ), the global business advisory firm ... enterprise value (the "Company"), announced that it has ... that were formerly included within the Corporate Finance/Restructuring ... Consulting segment to form a single integrated practice ...
(Date:5/21/2013)... 21, 2013 Custom Learning Designs, ... eLearning solution using Tin Can API combined with ... CLD is a leading developer of training content ... companies worldwide. , Tin Can API is ... learners and trainers more accurately measure the Return ...
(Date:5/21/2013)... The results of a new study led by ... computational evidence that nucleation of ice in small ... understanding water,s behavior at the nanoscale. The formation ... basic scientific research question whose answer also has ... , The crystallization of ice from supercooled ...
(Date:5/21/2013)... , May 21, 2013 The ... and Transplant Association) is the biggest congress in ... therapy. Nearly 10,000 participants are in Istanbul ... latest research findings. New pioneering studies have been presented: ... FERRIC PYROPHOSPHATE (SFP) ADMINISTERED VIA HEMODIALYSATE REDUCES ESA USE" ...
Breaking Biology Technology:FTI Consulting Releases Realigned Segment Information Reflecting Newly Combined Health Solutions Practice 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3Study led by GW professor provides better understanding of water's freezing behavior at nanoscale 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3
... Madison Internet service provider SupraNet plans to ... the Aidmatrix Foundation, a global disaster-relief firm run by ... CEO Bryan Chan said in a press release that ... number of recent disasters the charity is responding to, ...
... of Wisconsin-Madison MBA program was ranked 51st in ... U.S. public university programs by the London Financial Times ... , ,These rankings are based on alumni careers and ... data provided by the schools and a survey of ...
... development assessment group for its high quality of life and ... States, released last week by the non-profit Corporation for Enterprise ... in business vitality and development capacity, based on 2004 data. ... subcategories that made up those three overall marks. , ,Perhaps ...
Cached Biology Technology:
(Date:5/21/2013)... path of insulin action in cells in precise detail ... understanding what goes wrong in diabetes. , The ... James from Sydney,s Garvan Institute of Medical Research, is ... prestigious journal Cell Metabolism . , First discovered ... role in the body because it helps us lower ...
(Date:5/20/2013)... 2013) University of Minnesota Medical School researchers from ... with the University,s Brain Tumor Program, have developed a ... (MPNST) that allow them to discover new genes and ... research was published this week in the journal ... method, researchers in the lab of David Largaespada, Ph.D., ...
(Date:5/20/2013)... planning grant will help establish the Center for Advanced ... University of Illinois at Urbana-Champaign and Worcester Polytechnic Institute ... to research in drying moist, porous materials such as ... chemical products; textiles; and biopharmaceuticals," said Hao Feng, a ... nutrition and the Illinois site director. , According to ...
Breaking Biology News(10 mins):Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3U of M researchers develop model for better testing, targeting of MPNST 2NSF approves planning grant for Center for Advanced Research in Drying 2
... are two of the most invasive species on the planet yet ... Queen Mary, University of London. The study, published in the ... crayfish and carp in Kenya,s Lake Naivasha between 2001 and 2008. ... and have adopted a central role in the food web for ...
... research discovery by a team of Stanford and European scientists ... be able to avoid limb amputation related to ischemia. A ... Journal suggests that the delivery of genes for ... "VEGF" may successfully cause the body to grow new blood ...
... in the US, researchers at the University of Gothenburg have found ... to film how proteins work at molecular level. Mapping ... could be the key to cures for everything from cancer to ... of Gothenburg, and his research group were among the first in ...
Cached Biology News:Carp dominate crayfish in invasive species battleground 2Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs 2More effective method of imaging proteins 2
... W x H): 17 3/4" x ... 12 slidesTime: Programmable 0 - 100 hoursControl: ... hybridization steps 40 user programmable protocols 3 ... temperature) Rapid temperature ramp-up from 37 - ...
Defender against cell death 1...
Human Osteocalcin (1-22) mature form. Also reacts with Osteocalcin (1-44) and Osteocalcin (1-49). No reactivity with Bone sialoprotein....
HSV-1 gE Envelope Protein (9H3)...
Biology Products: